TechMARK movers: Smith & Nephew results please market

10th Feb 2011 12:19

Medical products supplier Smith & Nephew reported a strong rise in 2010 profit as well as the departure of its boss. Smith & Nephew saw revenue in the final quarter of 2010 remain more or less unchanged from a year earlier at $1,066m. That brought full year revenue up to $3,962m, up 4% from $3,772m a year earlier - just above forecasts. Full year profit rose from $670m to $895m.David Illingworth, chief executive of Smith & Nephew is to leave, sparking renewed speculation that some takeover activity is afoot. He'll be replaced by Olivier Bohuon, previously chief executive of Pierre Fabre and executive vice-president at Abbott Laboratories.Antisoma has been hit by profit-taking after it put itself up for sale earlier this week. AIM-quoted ORA has increased its stake to 16.1%. FTSE TechMARK - Risers Phytopharm (PYM) 9.43p +12.93%Alterian (ALN) 207.75p +3.88%Kofax (KFX) 469.75p +3.24%KCOM Group (KCOM) 59.00p +2.16%Promethean World (PRW) 63.00p +2.02%Autonomy Corporation (AU.) 1,603.00p +1.97%Smith & Nephew (SN.) 724.00p +1.69%Sepura (SEPU) 45.50p +1.11%Sage Group (SGE) 289.00p +0.80%Axis-Shield (ASD) 302.25p +0.67%FTSE TechMARK - Fallers Antisoma (ASM) 2.26p -5.44%Parity Group (PTY) 30.00p -4.76%Vislink (VLK) 20.75p -3.49%ARM Holdings (ARM) 588.00p -2.33%Filtronic (FTC) 34.00p -2.16%Skyepharma (SKP) 36.25p -2.03%Sinclair Pharma (SPH) 37.75p -1.95%Dialight (DIA) 547.50p -1.53%Innovation Group (TIG) 16.75p -1.47%Anite (AIE) 67.75p -1.45%